188 related articles for article (PubMed ID: 23506018)
1. Isocitrate lyase: a potential target for anti-tubercular drugs.
Sharma R; Das O; Damle SG; Sharma AK
Recent Pat Inflamm Allergy Drug Discov; 2013 May; 7(2):114-23. PubMed ID: 23506018
[TBL] [Abstract][Full Text] [Related]
2. Identification of a novel inhibitor of isocitrate lyase as a potent antitubercular agent against both active and non-replicating Mycobacterium tuberculosis.
Liu Y; Zhou S; Deng Q; Li X; Meng J; Guan Y; Li C; Xiao C
Tuberculosis (Edinb); 2016 Mar; 97():38-46. PubMed ID: 26980494
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and characterization of pyruvate-isoniazid analogs and their copper complexes as potential ICL inhibitors.
Shingnapurkar D; Dandawate P; Anson CE; Powell AK; Afrasiabi Z; Sinn E; Pandit S; Venkateswara Swamy K; Franzblau S; Padhye S
Bioorg Med Chem Lett; 2012 May; 22(9):3172-6. PubMed ID: 22475559
[TBL] [Abstract][Full Text] [Related]
4. Targeting isocitrate lyase for the treatment of latent tuberculosis.
Bhusal RP; Bashiri G; Kwai BXC; Sperry J; Leung IKH
Drug Discov Today; 2017 Jul; 22(7):1008-1016. PubMed ID: 28458043
[TBL] [Abstract][Full Text] [Related]
5. Salicylanilide derivatives block Mycobacterium tuberculosis through inhibition of isocitrate lyase and methionine aminopeptidase.
Krátký M; Vinšová J; Novotná E; Mandíková J; Wsól V; Trejtnar F; Ulmann V; Stolaříková J; Fernandes S; Bhat S; Liu JO
Tuberculosis (Edinb); 2012 Sep; 92(5):434-9. PubMed ID: 22765970
[TBL] [Abstract][Full Text] [Related]
6. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
7. Potential inhibitors for isocitrate lyase of Mycobacterium tuberculosis and non-M. tuberculosis: a summary.
Lee YV; Wahab HA; Choong YS
Biomed Res Int; 2015; 2015():895453. PubMed ID: 25649791
[TBL] [Abstract][Full Text] [Related]
8. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
Tomioka H
Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
[TBL] [Abstract][Full Text] [Related]
9. Phenolic N-monosubstituted carbamates: Antitubercular and toxicity evaluation of multi-targeting compounds.
Krátký M; Janďourek O; Baranyai Z; Novotná E; Stolaříková J; Bősze S; Vinšová J
Eur J Med Chem; 2019 Nov; 181():111578. PubMed ID: 31401536
[TBL] [Abstract][Full Text] [Related]
10. Screening of Anti-mycobacterial Phytochemical Compounds for Potential Inhibitors against Mycobacterium Tuberculosis Isocitrate Lyase.
Tiwari A; Kumar A; Srivastava G; Sharma A
Curr Top Med Chem; 2019; 19(8):600-608. PubMed ID: 30836915
[TBL] [Abstract][Full Text] [Related]
11. Structure-based screening and molecular dynamics simulations offer novel natural compounds as potential inhibitors of Mycobacterium tuberculosis isocitrate lyase.
Shukla R; Shukla H; Sonkar A; Pandey T; Tripathi T
J Biomol Struct Dyn; 2018 Jun; 36(8):2045-2057. PubMed ID: 28605994
[TBL] [Abstract][Full Text] [Related]
12. [Prospects for development of new antituberculous drugs].
Tomioka H
Kekkaku; 2002 Aug; 77(8):573-84. PubMed ID: 12235850
[TBL] [Abstract][Full Text] [Related]
13. [Inhibitory effects of 10-23 deoxyribozyme targeting ICL gene on the expression of isocitrate lyase and the infection of Mycobacterium tuberculosis in macrophages].
Li JM; Li N; Zhu DY; Yi ZJ; Liu YH; Yang C; He YL
Zhonghua Jie He He Hu Xi Za Zhi; 2006 Aug; 29(8):531-5. PubMed ID: 17074266
[TBL] [Abstract][Full Text] [Related]
14. Lysine succinylation of Mycobacterium tuberculosis isocitrate lyase (ICL) fine-tunes the microbial resistance to antibiotics.
Zhou M; Xie L; Yang Z; Zhou J; Xie J
J Biomol Struct Dyn; 2017 Apr; 35(5):1030-1041. PubMed ID: 27023679
[TBL] [Abstract][Full Text] [Related]
15. 5-Nitro-2,6-dioxohexahydro-4-pyrimidinecarboxamides: synthesis, in vitro antimycobacterial activity, cytotoxicity, and isocitrate lyase inhibition studies.
Sriram D; Yogeeswari P; Senthilkumar P; Naidu G; Bhat P
J Enzyme Inhib Med Chem; 2010 Dec; 25(6):765-72. PubMed ID: 20569083
[TBL] [Abstract][Full Text] [Related]
16. Microbiology. A weak link in TB bacterium is found.
Helmuth L
Science; 2000 Aug; 289(5482):1123-5. PubMed ID: 10970221
[TBL] [Abstract][Full Text] [Related]
17. Salicylanilide pyrazinoates inhibit in vitro multidrug-resistant Mycobacterium tuberculosis strains, atypical mycobacteria and isocitrate lyase.
Krátký M; Vinšová J; Novotná E; Stolaříková J
Eur J Pharm Sci; 2014 Mar; 53():1-9. PubMed ID: 24333643
[TBL] [Abstract][Full Text] [Related]
18. Advances in mycobacterial isocitrate lyase targeting and inhibitors.
Krátký M; Vinšová J
Curr Med Chem; 2012; 19(36):6126-37. PubMed ID: 23092127
[TBL] [Abstract][Full Text] [Related]
19. Isocitrate lyase mediates broad antibiotic tolerance in Mycobacterium tuberculosis.
Nandakumar M; Nathan C; Rhee KY
Nat Commun; 2014 Jun; 5():4306. PubMed ID: 24978671
[TBL] [Abstract][Full Text] [Related]
20. DNAzymes targeting the icl gene inhibit ICL expression and decrease Mycobacterium tuberculosis survival in macrophages.
Li J; Zhu D; Yi Z; He Y; Chun Y; Liu Y; Li N
Oligonucleotides; 2005; 15(3):215-22. PubMed ID: 16201909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
